[Effects of resveratrol on inflammatory process induced by focal cerebral ischemia-reperfusion in rats].
OBJECTIVE
To investigate the protective effects of resveratrol on inflammatory process induced by focal cerebral ischemia-reperfusion in rats.


METHODS
Rats were pretreated with resvreratrol at the dose of 10, 20, 40 mg kg(-1) for 7 days and then subjected to cerebral ischemia/reperfusion induced by a middle cerebral artery occlusion (MCAO). The infarct volume and the neurological deficit were determined by the method of TTC (2, 3, 5-triphenylterazolium chloride) staining and Longa's score. The permeability of blood-brain barrier (BBB) was evaluated by measurement of the evans blue (EB) content in the brain with spectrophotometer. The content of interleukin-lbeta, interleukin-6 (IL-6, IL-1beta) in serum and tumor necrosis factor-alpha (TNF-alpha), myeloperoxidase (MPO) in brain were determined by radio-immunoassay and ELISA assay.


RESULTS
Resveratrol reduced infarct volume, ameliorated the neurological deficit and the permeability of BBB, the content of IL-6, IL-1beta in serum and TNF-alpha, MPO activity in brain tissue also were significantly decreased.


CONCLUSIONS
These results showed that resveratrol had protective effects on cerebral injury by inhibiting the releasing of the inflammatory mediators after ischemia/reperfusion injury.
Liu
Yong-gang
YG
Department of pharmaceutical, Guangdong Province Corps Hospital, Chinese People's Armed Force, Guangzhou 510515, China. liuyg1999@163.com
Wang
Xiao-dong
XD
Zhang
Xiao-bing
XB
D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D002545:Brain Ischemia / Q000150:complications; D020244:Infarction, Middle Cerebral Artery / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D018836:Inflammation Mediators / Q000097:blood*; D053583:Interleukin-1beta / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology; D009195:Peroxidase / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000150:complications*; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D018836:Inflammation Mediators; D053583:Interleukin-1beta; D015850:Interleukin-6; D018696:Neuroprotective Agents; D013267:Stilbenes; D014409:Tumor Necrosis Factor-alpha; D009195:Peroxidase; D000077185:Resveratrol